TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 27 2022 - 3:15PM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced that the
Company plans to discuss the complete Phase 1 portion of the
gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid
tumors in a premarket press release and conference call to be held
on Wednesday, September 28th, 2022 at 8:00am E.T.
In order to participate in the conference call,
please register at https://bit.ly/3BTJ9Z7. Participants can
register via this link up to ten minutes prior to start time. The
webcast and presentation will be made available on the TCR2
Therapeutics website in the Investors section under Events at
investors.tcr2.com/events. Following the live audio webcast, a
replay will be available on the Company's website for approximately
30 days.
About
TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Investor and
Media Contact:Carl MauchSenior
Director, Investor Relations and Corporate Communications(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about TCR2 Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles